Aruna Bio
3 known investors
Aruna Bio develops a proprietary neural exosome platform and a lead therapeutic neural cell-derived exosome, AB126, designed to cross the blood-brain barrier. The company targets acute neurological conditions and chronic neurodegenerative diseases through mechanisms that reduce neuro-inflammation and promote neuro-protection and neuro-regeneration.
BiotechHealthtech
Investors · 3
Non-dilutive funding · 12 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2022 | $346.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $4.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $500K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $225K |
| Environmental Protection Agency (EPA) | Phase II | 2014 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $225K |
| National Science Foundation | Phase I | 2013 | $149.4K |
| Environmental Protection Agency (EPA) | Phase I | 2013 | $80K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $706.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2008 | $189.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2005 | $293.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2005 | $293.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Aruna Bio do?
- Aruna Bio develops a proprietary neural exosome platform and a lead therapeutic neural cell-derived exosome, AB126, designed to cross the blood-brain barrier. The company targets acute neurological conditions and chronic neurodegenerative diseases through mechanisms that reduce neuro-inflammation and promote neuro-protection and neuro-regeneration.
- Who are Aruna Bio's investors?
- Aruna Bio's investors include Eshelman Ventures, LLC, Evolution VC Partners, GRA Venture.